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Abstract
Dendritic cells (DCs) are antigen presenting cells that activate T cells and determine the outcome of immune
response. In addition to their important function in defense against pathogens, DCs are increasingly recognized
as playing a crucial role in the regulation of immune tolerance. Plasticity of DCs with different maturity status
and functions enable them to be exploited as potential cell-based therapy to restore immune tolerance in auto-
immune diseases. Various ex vivo methods have been developed to generate stable tolerogenic DCs that are able
to induce and maintain regulatory T cell homeostasis. The beneficial effect of tolerogenic DCs have been studied
in murine autoimmune models with promising results. Systemic lupus erythematosus (SLE) is a prototypic
multi-systemic autoimmune disease characterized by autoantibody production and deposition of immune com-
plexes in organs. There are evidences that dysregulated DCs play a pivotal role in the initiation and perpetuation
of lupus disease. Peripheral blood monocytes in SLE patients were found to have active phenotype with acceler-
ated differentiation into DCs efficient in antigen presentation. Plasmacytoid DCs in SLE patients produce high
levels of interferon-alpha, the signature cytokine of this disease, that cause a positive feedback loop in the ampli-
fication of activation of innate and adaptive immunity. Furthermore, manipulation of DCs via toll-like receptor
knockout in a murine lupus model leads to alteration in disease severity and survival. Thus, tolerogenic DCs
may appear as a potential cell-based therapeutic option in SLE.
Key words: disease aetiology and pathogenesis – animal models, disease aetiology and pathogenesis – human,
innate immunity, systemic lupus erythematous.
INTRODUCTION
Dendritic cells (DCs) are innate cells involved in the
first line of defense against pathogens. They are highly
efficient in antigen presentation to T lymphocytes,
resulting in elicitation of the second line of immune
defense. The past decades of intensive research in DC
biology have revealed a key function of DCs in bridging
innate and adaptive immunity, as well as a pivotal role
in the regulation of immunity and immune tolerance.1
DCs exhibit plasticity in their maturity status and func-
tions and have been exploited in clinical application as
cell-based vaccine and immunotherapy in cancer,
allergy and organ transplantation, and emerge as
appealing targets in the treatment of autoimmune
diseases.2
Systemic lupus erythematosus (SLE) is a multi-
systemic autoimmune disease that is characterized by
a plethora of circulating autoantibodies3 with immune
complexes deposition in organs leading to inflamma-
tion and damage.4 The mainstay of treatment of SLE
involves high-dose corticosteroids and immunosup-
pressive agents that are associated with significant
adverse effects. Extensive research effort has been
made in the elucidation of the pathogenesis of lupus
and to facilitate identification of key soluble or cellu-
lar immune targets that have potential therapeutic
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implications. Recent development of biologic thera-
pies focuses chiefly on B cell-targeted treatment as
plasma cells, the terminal effector cells of B cell line-
age, and produce autoantibodies and enhanced forma-
tion of immune complexes.5 On the other hand, DCs
at the upstream of the dysregulated innate and adap-
tive immune responses in SLE, have been shown to
be involved in the initiation and perpetuation of this
disease that form the basis for potential DC-targeted
treatment in this condition.
DCs ARE CONTROLLERS OF IMMUNITY
DCs are distributed ubiquitously in the body, particu-
larly in barrier tissues such as the respiratory and
gastrointestinal tracts that are kept under constant sur-
veillance for microbial invasion. DCs respond quickly
to environmental stimuli. They are specialized with
expression of pattern-recognition receptors (PRRs)
including Toll-like receptors (TLRs), nucleotide-binding
oligomerization domain (NOD)-like receptors and
retinoic acid-inducible gene 1 (RIG-I)-like receptors,
that enable them to sense and recognize pathogen-
associated molecular patterns (PAMP) on cell surfaces
of microbes.6 Some TLRs are expressed on DC cell sur-
faces, whereas some are found in the intracytoplasmic
compartment that allow DCs to recognize microbial
antigens, DNA or RNA,7 as well as endogenous signals
such as damage-associated molecular patterns (DAMPs)
which are intracellular factors released by dying cells in
the context of tissue injury or inflammation.8
DCs are specific antigen-presenting cells and they
capture, process and present antigens to T cells leading
to activation of antigen-specific T cells, and shaping the
immune response by priming and polarizing the differ-
entiation of na€ıve T cells into different T effector cells.9
Stimulation of DCs via TLRs leads to their activation
and maturation.10 Activated DCs upregulate expression
of chemokine receptor CCR7 and migrate to T-cell areas
in secondary lymphoid tissue. Exogenous antigens
taken up by DCs are processed and loaded on major
histocompatibility complex (MHC) Class II molecules
on DC cell surface for T cell recognition. Communica-
tion between DCs and T cells occurs upon cognate
interaction in the immunological synapse. Activated
DCs acquire further maturation upon DC-T cell interac-
tion, and via activation of antigen-specific T cells, adap-
tive immune response is initiated and is mediated by
concerted signals at the DC-T cell encounter.11 Recogni-
tion and binding of peptide-loaded MHC molecules by
T cell receptor complex on T cells contributes the first
signal to T cell activation. Induction of DC to matura-
tion leads to expression of high levels of MHC Class II
and upregulation of cell surface expression of co-stimu-
latory molecules, including CD80 and CD86 that binds
to CD28 on T cells, and CD40 that binds to CD40L
expressed by activated T cells.12 The second signal gen-
erated by these co-stimulatory molecules synergises to
augment the strength for T cell activation. Antigen-
loaded activated DCs also secrete cytokines which com-
prises the third signal that drives differentiation of na€ıve
T cells into T cells with distinct effector functions and
determines the outcome of the induced immune
response. Production of high levels of interleukin
(IL)-12 and IL-4 leads to differentiation into T helper
(Th)1 and Th2 cells that are involved in cellular immu-
nity and humoral immunity, respectively. Both Th17
and regulatory T cells (Tregs) require transforming
growth factor (TGF)-b for their induction, whereas high
levels of IL-6 favor differentiation toward Th17 cells.13
Tregs are T effector cells that possess suppressive func-
tion on other immune cells and play an important role
in the regulation and maintenance of peripheral toler-
ance. Natural Tregs (nTreg) are derived in the thymus,
whereas inducible Tregs (iTreg) are induced by antigens
and cytokines in the periphery.14 Th17 cells produce
IL-17, an inflammatory cytokine that mediates the path-
ophysiology of inflammatory diseases such as rheuma-
toid arthritis (RA)15 and SLE.16
DCs ARE REGULATORS OF PERIPHERAL
TOLERANCE
Not only are DCs important in immunity, DCs have
also been found to play a crucial role in immune toler-
ance,17 the breakdown of which leads to emergence of
autoimmunity. During T cell development, circulating
T lymphocytes that are reactive to self-antigens are elim-
inated under the process of central tolerance in the thy-
mus. However, some autoreactive T lymphocytes escape
elimination and persist in the periphery. Peripheral tol-
erance acts as another checkpoint in peripheral tissue
where autoreactive T cells are curbed from activation
and contribution to autoimmunity. At the steady state
where there is absence of pathogen or inflammation,
DCs exist in immature status and possess high capabil-
ity of antigen uptake.18 Immature DCs that have taken
up endogenously expressed antigens in the periphery
migrate to lymph nodes, interact with T cells and
induce peripheral tolerance.19 Presentation of endoge-
nous antigen to T cells by immature DCs in the absence
of co-stimulatory signals results in T cell anergy, a state
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of T cell hyporesponsiveness.20 Induction of peripheral
tolerance can be achieved by DC-T cell interaction via
mechanisms including T cell deletion, induction of T
cell anergy, cytokine deviation and induction of
Tregs.21
REGULATION OF IMMUNE TOLERANCE IS
NOT DC SUBSET-RESTRICTED
DCs are derived from bone marrow precursors and
comprise heterogeneous populations. In a simplistic
view, there are generally two major subsets, namely,
myeloid DCs (mDCs) and plasmacytoid DCs (pDCs),
in peripheral blood in humans. These DC subsets
express different PRRs and both can elicit immune
response depending on the inciting stimuli encoun-
tered.22 Compared to mDCs, pDCs are less capable of
antigen uptake and presentation but they are high pro-
ducers of type I interferon which is essential for anti-
viral immunity. Homologous counterparts of these two
subsets can be found in mice.
The contribution of DCs to immunity and immune
tolerance can be illustrated by manipulating these cells
in animal models. Experimental ablation in mice of
conventional DCs (cDCs) that are homologous to
human mDCs, were not found to affect T cell or Treg
homeostasis.23 However, constitutional ablation of all
DC subsets in mice is associated with fatal autoimmune
manifestations, including circulating anti-nuclear anti-
bodies, increased Th1 and Th17 infiltration into organs
and development of inflammatory colitis.24 On the
other hand, exogenous administration of Flt3-ligand
that boost DC populations was accompanied by expan-
sion of nTregs and resulted in alleviation of inflamma-
tory colitis25 and prevention of death in the graft-
versus-host model.26 These findings suggest that DCs
are controllers at the interface of immunity and
immune tolerance and their regulatory function is not
restricted to a particular DC subset.
THE ROLE OF DCs IN THE PATHOGEN-
ESIS OF SLE
Aberrant apoptosis27 with inefficient clearance of apop-
totic cells is an important feature in lupus pathogenesis
and provides continual supply of autoantigens. Our
group had previously shown that macrophages in SLE
patients were deficient in swift removal of apoptotic
cells28 which was related to soluble serum factors,29
resulting in accumulation of apoptotic materials.
Although uptake of apoptotic DCs by immature DCs
has been shown to render DCs tolerogenic,30 excessive
apoptosis leads to secondary necrosis, allowing DC acti-
vation and self-antigen presentation to T cells in an
immunogenic context.31 Challenge by necrotic cell- but
not apoptotic cell-loaded DCs was found to induce SLE
disease in a murine model with susceptible genetic
background,31 suggesting that DCs are key immune
cells maintaining immune tolerance in SLE. The role of
DCs as regulators of immunity and immune tolerance
was further demonstrated by constitutional deletion of
both cDCs and pDCs in the MRL/lpr murine lupus
model. Although ablation of DCs did not fully abolish
T cell activation and inflammatory kidney infiltrate,
adaptive immune responses, including expansion
and differentiation of autoreactive T cells, plasma-
blast differentiation and production of serum anti-
double-stranded DNA (anti-dsDNA) antibodies were
found to be DC-dependent.32
Experiments on TLR signaling in DCs and manipula-
tion of TLR expression in a murine lupus model also
support a key role of DCs bridging innate and adaptive
immunity in the pathogenesis of SLE. Human mDCs
express TLR 1, 2, 4, 5 and 8 and are potent inducers of
Th1 response. They produce pro-inflammatory cyto-
kines, including tumor necrosis factor (TNF)-a and
IL-12 upon stimulation by various ligands.33 On the
other hand, TLR7 and TLR9 are constitutively expressed
by pDCs and are involved in immune response toward
self DNA and RNA in SLE patients.34 Gene knockout
models of various TLRs have been shown to have differ-
ent effects on lupus phenotype and disease severity.
TLR9 knockout in lupus mice resulted in increased
number of activated pDCs and T lymphocytes, acceler-
ated glomerulonephritis and reduced survival.35 While
TLR9 was found to play a protective role in murine
lupus, TLR7 signaling was shown to mediate autoanti-
body production, interferon-alpha (IFN-a) production
and lupus disease progression.
There is increasing evidence revealing the important
contribution of dysregulated DCs to the initiation and
perpetuation of SLE. Peripheral blood monocytes in
SLE patients have a propensity to develop into DCs
which have more mature phenotype with expression of
higher levels of co-stimulatory molecules and possess
higher antigen presentation and T cell stimulatory
capacity,36 an effect mediated by IFN-a. Circulating
pDCs in lupus patients have upregulated expression of
chemokine receptors that facilitate their infiltration into
inflammatory organs such as the kidney in active lupus
nephritis.37 Furthermore, pDCs activated by endoge-
nous ligands, particularly nucleic acid that binds to
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immune complexes, produce high levels of IFN-a which
represents a characteristic cytokine signature in SLE.38
IFN-a produced by pDCs causes maturation of mDCs,
thus promoting downstream T and B cell activation
with formation of immune complexes that in turn, bind
to self nucleic acid and stimulate pDCs, forming a posi-
tive feedback loop amplifying the dysregulated innate
and adaptive immune responses (Fig. 1). IFN-a also
has a direct effect on B cells inducing plasma cell differ-
entiation,39 leading to production of autoantibodies
and immune complexes perpetuating the lupus disease.
All these evidences suggest that SLE patients may benefit
from DC-based therapy in the restoration of immune
tolerance.
EXPLOITATION OF TOLEROGENIC DCs IN
THERAPEUTICS
Plasticity of DCs with different maturity status and
functions involved in the regulation of immunity and
immune tolerance allows them to be exploited as tol-
erogenic DCs for their clinical applications in organ
transplantation40 and autoimmune diseases41 with
the goal of maintenance of peripheral tolerance. Anti-
gen uptake and presentation in the context of low
co-stimulatory molecules expressed by immature DCs
is associated with immune tolerance. On the other
hand, mature DCs express high-level MHC and
co-stimulatory molecules, have potent antigen presen-
tation and T cell activation capability and produce
high levels of IL-12.42 As safe and efficacious cell-
based therapy in autoimmune diseases, it is crucial
that tolerogenic DCs remain maturation-resistant
without losing their immunomodulatory effect or
exacerbating the underlying inflammatory condition.
Immature and semi-mature DCs were shown to be
unstable and acquire maturity upon encounter with
the pro-inflammatory environment after administra-
tion to the recipient.43,44
In recent years, extensive research has established a
variety of ex vivo methods which can generate DCs with
stable tolerogenic functions to be applied clinically as
autologous cell-based therapy. While these DCs may
express low to intermediate levels of co-stimulatory
molecules, these tolerogenic DCs are characterized by
their tolerogenic function with suppressive effects on
allogeneic antigen-specific T cells, distinct cytokine pro-
files with production of low levels of IL-12 but high lev-
els of IL-10, and expression of CCR7 that allows them
to migrate to lymph nodes for T cell interaction.45 Gen-
erally, tolerogenic DCs can be derived by intervening
DCs at their checkpoints of differentiation, maturation
or activation (reviewed in Morelli and Thomson40). In
brief, DCs can be derived from peripheral blood mono-
cytes and manipulated to acquire tolerogenic function
by treatment using immunosuppressive cytokines such
as IL-10 and TGF-b, or immunosuppressive drugs
including cyclosporine, rapamycin, mycophenolate
Figure 1 Simplified diagram illustrating
the role of myeloid and plasmacytoid
dendritic cells mediating innate and
adaptive immune response in lupus
pathogenesis.
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mofetil (MMF), vitamin D3, dexamethasone or other
agents like N-acetyl-cysteine, glucosamine, human
leukocyte antigen G (HLA-G) or cyclic adenosine
30,50-monophosphate (AMP) inducers such as prosta-
glandin E2 (PGE2). Methods of genetic engineering can
also be applied to generate tolerogenic DCs, involving
induction of expression of immunosuppressive cyto-
kines such as IL-10 and TGF-b in DCs, and insertion of
oligodeoxynucleotide that silences NF-kB pathway-
related signaling molecules which are involved in DC
maturation.
The effect of tolerogenic DCs in the maintenance of
peripheral tolerance are mediated by different mecha-
nisms, including induction of T cell anergy, T cell
apoptosis, cytokine deviation to Th2 and expansion of
nTreg, Foxp3+ Treg as well as induction of IL-10-pro-
ducing Treg, depending on the method adopted to
generate these tolerogenic DCs. For instance, manipu-
lation by rapamycin46 was shown to expand Foxp3+
Tregs, whereas vitamin D3 or MMF can induce Treg
from na€ıve T cells.47 In addition, tolerogenic DCs may
also induce peripheral tolerance mediated by induction
of expression of indoleamine 2,3 deoxygenase (IDO)
or programmed death ligand 1 (PDL-1) on DCs. Com-
bination of PGE2 and TNF-a is an example of generat-
ing tolerogenic DCs that express IDO and IL-10.48 IDO
catalyses degradation of tryptophan into kynurenines49
which leads to suppression of allogeneic T cell prolifer-
ation.50 IDO activity can also lead to enrichment of
nTreg.51 PDL-1 is an inhibitory molecule on some DCs
that are involved in the maintenance of peripheral
tolerance.52 Furthermore, some tolerogenic DCs also
express heme oxygenase-1 (HO-1)53 or Epstein-Barr
virus-induced gene 3 (EBI3)54 that mediates toleroge-
nicity via inhibition of allogeneic T cell proliferation or
induction of IFN-c production by double negative T
cells, respectively.
A previous experiment revealed that monocyte-
derived DCs in direct cell contact with CD4+ CD25+
Treg acquired a less mature phenotype with impaired
antigen presentation capability.55 These DCs in cocul-
ture with Treg express high levels of IL-10 that act on
the DCs in an autocrine fashion with induction of neg-
ative regulatory molecules such as B7-H4 which have a
suppressive effect on proliferation of allogeneic T
cells.56 Indeed, the induced tolerogenic DCs and
Tregs isolated ex vivo, after induction of tolerance by
anti-CD45RB monoclonal antibody and an analogue
of immunosuppressive drugs in a transplant model,
have been shown to promote further generation of
functional Tregs from na€ıve T cells and generation of
tolerogenic DCs from bone marrow progenitors,
respectively.57 Thus, tolerogenic DCs regulate induction
and maintenance of homeostasis of Tregs, which in
turn inhibit DC maturation and promote generation of
tolerogenic DCs, contributing to a feedback loop of tol-
erogenic DC-Treg interaction in sustaining the mainte-
nance of peripheral tolerance (Fig. 2).
Figure 2 Positive feedback loop for tol-
erogenic dendritic cells and regulatory T
cells in the maintenance of peripheral
tolerance.
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TOLEROGENIC DCs AS CELL-BASED
THERAPY IN ANIMAL STUDIES AND
CLINICAL TRIALS
Adoptive transfer of tolerogenic DCs generated by dif-
ferent methods have been studied in a murine model of
autoimmune diseases, particularly in collagen-induced
arthritis, with promising results.58 DCs are believed to
play a key role in the initiation and perpetuation of
RA.59 In RA, chemokine receptor profile expression sug-
gested that immature DCs were recruited into the rheu-
matoid joint which functioned as ectopic lymphoid
tissue and underwent further development into mature
DCs.60 DCs in rheumatoid synovium and synovial fluid
had a more mature phenotype expressing high levels of
MHC Class II and co-stimulatory molecules compared
to DCs in peripheral blood and these DCs strongly
induced T cell activation and proliferation in response
to type II collagen.61 Administration of type II collagen
pulsed tolerogenic DCs were shown to alleviate disease
severity, induce IL-10-producing T cells and reduce the
number of Th17 cells in collagen-induced arthritis.62
Tolerogenic DCs have also been studied in other
murine autoimmune models with alleviating effect on
disease severity, such as the administration of b2-glyco-
protein-I loaded tolerogenic DCs in mice with anti-
phospholipid syndrome63 and tolerogenic DCs with
silenced expression of CD40 and IL-23 in experimental
autoimmune encephalomyelitis.64 Tolerogenic DCs
generated by the plant extract curcumin from bone mar-
row-derived DCs, were found to induce Tregs that med-
iated inhibition of antigen-specific colitis in a mouse
model.65
In humans, IL-10 and TGF-b1 generated tolerogenic
DCs from monocyte-derived DCs, that were pulsed
with pancreatic islet antigens, and were found to induce
antigen-specific T cell hyporesponsiveness and were
associated with better glycemic control in patients with
type 1 diabetes.66 Indeed, the first clinical trial applying
tolerogenic DCs as cell-based therapy was carried out in
2009 in patients with insulin-dependent diabetes mell-
itus.67 These patients were given three doses of
bi-weekly subcutaneous injection of tolerogenic DCs
which had silenced gene expression of various co-stim-
ulatory molecules. The treatment was not associated
with adverse effects or emergence of disease-associated
autoantibodies, although no difference in clinical out-
come was observed compared to the control group over
12 months. The effect of tolerogenic DCs derived by ex
vivo treatment using NF-kB inhibitor and pulsed with
citrullinated peptides was examined in patients with
active RA. A single dose of these DCs was injected sub-
cutaneously and the treatment was well tolerated with
modest improvement in disease activity 3 and
6 months after injection.68 There is another on-going
clinical trial applying intra-articular injection of tolero-
genic DCs generated by treatment of vitamin D3 and
dexamethasone.69
DC TARGETED THERAPY IN SLE
In vitro experiments showed that monocyte-derived
DCs from SLE patients in co-culture with iC3b-
opsonized apoptotic cells demonstrated tolerogenic
properties.70 Our group applied combinational treat-
ment of vitamin D3 and dexamethasone to monocyte-
derived DCs and we found that tolerogenic DCs gener-
ated using these pharmacological agents can induce
IL-10-producing T cells with regulatory function and
downregulate IFN-c and IL-17 production from mature
T cells.71 Tolerogenic DCs as cell-based therapy have not
been examined in vivo in a murine model or human
lupus so far. As SLE involves a diversity of autoantigens,
generation of tolerogenic DCs with broader antigen
specificities warrants further studies. Indeed, administra-
tion of an immunomodulatory peptide p140 derived
from small nuclear ribonucleoprotein (snRNP), a splice-
osomal autoantigen, to MRL/lpr mice demonstrated a
phenomenon of tolerance spreading with broadened
immunoreactivity and resultant downregulation of
autoreactive T and B cell responses to other spliceoso-
mal proteins and self-antigens associated with SLE.72
On the other hand, the application of non-antigen
loaded tolerogenic DCs together with suboptimal
immunosuppression was shown to induce antigen-spe-
cific allograft tolerance in an organ transplantation
model and was likely related to in vivo uptake of endoge-
nous antigens by the injected DCs.73 Another peptide
derived from nucleosomal histone was shown to delay
onset of disease, reduce anti-dsDNA antibody levels,
suppress Th17 infiltration into the kidneys and prolong
lifespan in lupus-prone mice, the effect of which was
DC-dependent and involved increased production of
TGF-b, reduced IL-6 and induction of Tregs.74 These
studies provide evidences to support DC-targeted treat-
ment as an appealing tool in the treatment of SLE.
TARGETING DCs BEYOND CELL-BASED
THERAPY
Recent understanding on the regulatory effects of
exogenously administered tolerogenic DCs reveals an
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important role of conventional DCs in the lymphoid
organs of the recipient.75 There was evidence to sug-
gest that after the infused tolerogenic DCs migrate to
secondary lymphoid tissue, they were taken up by the
local quiescent conventional DCs which mediate tol-
erogenicity via deletion of antigen-specific T effector
cells and enhanced numbers of Tregs.76 These quies-
cent conventional DCs may also be targeted in vivo by
administration of immunomodulatory peptides,72,74
autoantigen-coupled antibodies specific to DC surface
receptors such as DEC20577 and tolerogenic
DC-derived microparticles.78
CONCLUSIONS
DCs are immune cells that bridge innate and adaptive
immune responses and are critical players at the inter-
face of immunity and immune tolerance. The regula-
tory function of DCs is not confined to a particular
DC subset but is recognized by their functional capa-
bility in the induction and maintenance of Treg
homeostasis. Plasticity of DCs with different maturity
status and functions enable them to be engineered
into stable tolerogenic DCs ex vivo as potential autolo-
gous cell-based therapy in the restoration of immune
tolerance in autoimmune diseases. As dysregulated
DCs have been shown to be involved in the initiation
and perpetuation of SLE, cell-based therapy using tol-
erogenic DCs may appear as a potential therapeutic
option for this disease. Before the goal of DC-targeted
therapy becomes a reality in the treatment of SLE,
more research is needed to study the DC biology in
this disease, the feasibility and clinical applicability of
cell-based therapy,79 such as the best methods of
induction of tolerogenicity, dosing, frequency, route
of administration and definition of achievement of
immune tolerance, as well as issues regarding good
manufacturing practice such as generation of clinical-
grade immune cells and quality control of these cell-
based therapies.
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